CAS Pharmacology & Medication-Assisted Treatment Flashcards
6 cards from real CAS practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 6 CAS Pharmacology & Medication-Assisted Treatment flashcards as text
Under the DATA 2000 waiver (now updated by the SUPPORT Act), which providers were originally authorized to prescribe buprenorphine for OUD in office-based settings?
Answer: Physicians who obtained a DEA X-waiver after completing required training
DATA 2000 established the DEA X-waiver system allowing qualifying physicians to prescribe buprenorphine for OUD after completing required training hours, later expanded to nurse practitioners and physician assistants.
Medication-Assisted Treatment (MAT) is best defined as the use of FDA-approved medications combined with:
Answer: Counseling and behavioral therapies to provide a whole-patient approach
SAMHSA defines MAT as a combination of FDA-approved medications with counseling and behavioral therapies, recognizing that medication alone is insufficient for long-term recovery.
A client on methadone maintenance asks why they cannot receive take-home doses after one week. The CAS should explain that take-home doses are granted based on:
Answer: Federal regulations that require demonstrated stability and time in treatment before take-home privileges are granted
Federal regulations (42 CFR Part 8) establish specific criteria—including time in treatment, urine drug screen results, and behavioral stability—that must be met before take-home doses are permitted.
Opioid-induced precipitated withdrawal can occur when buprenorphine is administered while full opioid agonists are still occupying receptors because:
Answer: Buprenorphine displaces full agonists from receptors but only partially activates them, causing abrupt withdrawal
Because buprenorphine has high receptor affinity, it displaces full agonists but produces only partial activation, causing sudden, severe withdrawal if given too soon after the last full agonist dose.
Which of the following is a primary advantage of extended-release injectable naltrexone (Vivitrol) over oral naltrexone for OUD?
Answer: It eliminates adherence problems associated with daily oral dosing
Extended-release injectable naltrexone is administered monthly by a clinician, eliminating the daily adherence challenge that frequently leads to oral naltrexone discontinuation.
When counseling a client prescribed MAT, the CAS should address common stigma by explaining that MAT medications are:
Answer: Evidence-based treatments that reduce mortality, decrease illicit drug use, and support sustained recovery
Robust evidence shows that MAT reduces overdose deaths, decreases illicit opioid use, lowers criminal activity, and improves treatment retention—providing a foundation for stable, long-term recovery.